Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilie Varey

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Oncotarget|June 5, 2018
Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapyGuillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, et al.
Cancers|April 30, 2021
Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation StudyGuillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, et al.
Cancer Research|December 8, 2017
Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical EfficacySylvain Simon, Virginie Vignard, Emilie Varey, et al.
European Journal of Dermatology : EJD|August 8, 2019
Efficacy and safety of nivolumab in metastatic melanoma: real-world practiceSolène Bocquet-Tremoureux, Emeric Scharbarg, Jean-Michel Nguyen, et al.
Acta Dermato-Venereologica|January 13, 2018
Blood Predictive Biomarkers for Nivolumab in Advanced MelanomaEdouard Chasseuil, Mélanie Saint-Jean, Hannah Chasseuil, et al.
Transplantation|May 21, 2020
Preclinical Assessment of Autologous Tolerogenic Dendritic Cells From End-stage Renal Disease PatientsLaurence Bouchet-Delbos, Amandine Even, Emilie Varey, et al.
Cancers|July 16, 2020
Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic <i>BRAF</i> or <i>NRAS</i>-Mutated Melanoma PatientsGuillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, et al.
JMIR Medical Informatics|June 25, 2024
Implementing a Biomedical Data Warehouse From Blueprint to Bedside in a Regional French University Hospital Setting: Unveiling Processes, Overcoming Challenges, and Extracting Clinical InsightMatilde Karakachoff, Thomas Goronflot, Sandrine Coudol, et al.
Experimental Dermatology|May 20, 2016
Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baselineAnne C Knol, Audrey Vallée, Guillaume Herbreteau, et al.
European Journal of Dermatology : EJD|August 21, 2020
Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel databaseStephane Dalle, Emilie Varey, Jean-Michel Nguyen, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Oncotarget|June 5, 2018
Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapyGuillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, et al.
Cancers|April 30, 2021
Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation StudyGuillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, et al.
Cancer Research|December 8, 2017
Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical EfficacySylvain Simon, Virginie Vignard, Emilie Varey, et al.
European Journal of Dermatology : EJD|August 8, 2019
Efficacy and safety of nivolumab in metastatic melanoma: real-world practiceSolène Bocquet-Tremoureux, Emeric Scharbarg, Jean-Michel Nguyen, et al.
Acta Dermato-Venereologica|January 13, 2018
Blood Predictive Biomarkers for Nivolumab in Advanced MelanomaEdouard Chasseuil, Mélanie Saint-Jean, Hannah Chasseuil, et al.
Transplantation|May 21, 2020
Preclinical Assessment of Autologous Tolerogenic Dendritic Cells From End-stage Renal Disease PatientsLaurence Bouchet-Delbos, Amandine Even, Emilie Varey, et al.
Cancers|July 16, 2020
Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic <i>BRAF</i> or <i>NRAS</i>-Mutated Melanoma PatientsGuillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, et al.
JMIR Medical Informatics|June 25, 2024
Implementing a Biomedical Data Warehouse From Blueprint to Bedside in a Regional French University Hospital Setting: Unveiling Processes, Overcoming Challenges, and Extracting Clinical InsightMatilde Karakachoff, Thomas Goronflot, Sandrine Coudol, et al.
Experimental Dermatology|May 20, 2016
Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baselineAnne C Knol, Audrey Vallée, Guillaume Herbreteau, et al.
European Journal of Dermatology : EJD|August 21, 2020
Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel databaseStephane Dalle, Emilie Varey, Jean-Michel Nguyen, et al.
Pageof 3